Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia – a longitudinal study

References

• von Dadelszen P, Menzies J, Magee LA. The complications of hypertension in pregnancy. Minerva Medica 2005;96:287–302.
   PubMedGoogle Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74.
   PubMed Web of Science ®Google Scholar
• Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am J Hypertens 2008;21:521–6.
   PubMed Web of Science ®Google Scholar
• Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009;113:1299–306.
   PubMed Web of Science ®Google Scholar
• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:391–403.
   PubMed Web of Science ®Google Scholar
• Alsnes IV, Janszky I, Forman MR, et al. A population-based study of associations between preeclampsia and later cardiovascular risk factors. Am J Obstet Gynecol 2014;211:657 e1.
   PubMed Web of Science ®Google Scholar
• Romero R, Lockwood C, Oyarzun E, Hobbins JC. Toxemia: new concepts in an old disease. Semin Perinatol 1988;12:302–23.
   PubMed Web of Science ®Google Scholar
• Witlin AG, Saade GR, Mattar F, Sibai BM. Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000;182:607–11.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592–4.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243–9.
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99.
   PubMed Web of Science ®Google Scholar
• Ganzevoort W, Rep A, de Vries JI, et al. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006;195:495–503.
   PubMed Web of Science ®Google Scholar
• Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006;30:16–19.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009;30:S38–S42.
   PubMed Web of Science ®Google Scholar
• Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–44.
   PubMed Web of Science ®Google Scholar
• Redman CW, Tannetta DS, Dragovic RA, et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012;33:S48–S54.
   PubMed Web of Science ®Google Scholar
• Seeho SK, Algert CS, Roberts CL, Ford JB. Early-onset preeclampsia appears to discourage subsequent pregnancy but the risks may be overestimated. Am J Obstet Gynecol 2016;215:785 e1–e8.
   Web of Science ®Google Scholar
• Burton GJ, Jauniaux E. What is the placenta? Am J Obstet Gynecol 2015;213:S6.e1–S6-8.
   Web of Science ®Google Scholar
• Kim CJ, Romero R, Chaemsaithong P, Kim JS. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol 2015;213:S53–S69.
   PubMed Web of Science ®Google Scholar
• Kim YM, Chaemsaithong P, Romero R, et al. The frequency of acute atherosis in normal pregnancy and preterm labor, preeclampsia, small-for-gestational age, fetal death and midtrimester spontaneous abortion. J Matern Fetal Neonatal Med 2015;28:2001–9.
   PubMed Web of Science ®Google Scholar
• Redline RW. Classification of placental lesions. Am J Obstet Gynecol 2015;213:S21–S8.
   PubMed Web of Science ®Google Scholar
• Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 2015;213:S21–8.
   PubMed Web of Science ®Google Scholar
• Vahanian SA, Lavery JA, Ananth CV, Vintzileos A. Placental implantation abnormalities and risk of preterm delivery: a systematic review and metaanalysis. Am J Obstet Gynecol 2015;213:S78–S90.
   PubMed Web of Science ®Google Scholar
• Ilekis JV, Tsilou E, Fisher S, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol 2016;215:S1–S46.
   PubMed Web of Science ®Google Scholar
• Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016;214:108.e1–e14.
   Web of Science ®Google Scholar
• Maulik D, De A, Ragolia L, et al. Down-regulation of placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016;214:279.e1–9.
   Web of Science ®Google Scholar
• Siddiqui MF, Nandi P, Girish GV, et al. Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker. Am J Obstet Gynecol 2016;215:361.e1–e15.
   Web of Science ®Google Scholar
• Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014;10:466–80.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Whitten A, et al. Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med 2013;41:485–504.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541–7. discussion 7–50.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18.
   PubMed Web of Science ®Google Scholar
• Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368–74.
   PubMed Web of Science ®Google Scholar
• Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303–9.
   PubMed Web of Science ®Google Scholar
• Gotsch F, Romero R, Kusanovic JP, et al. Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med 2008;21:389–402.
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Matsubara S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res 2008;31:1541–8.
   PubMed Web of Science ®Google Scholar
• Kim YN, Lee DS, Jeong DH, et al. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009;29:464–70.
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38.
   PubMed Web of Science ®Google Scholar
• Wikstrom AK, Larsson A, Akerud H, Olovsson M. Increased circulating levels of the antiangiogenic factor endostatin in early-onset but not late-onset preeclampsia. Reprod Sci 2009;16:995–1000.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 2010;35:155–62.
   PubMed Web of Science ®Google Scholar
• Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012;25:498–507.
   PubMed Web of Science ®Google Scholar
• Alahakoon TI, Zhang W, Trudinger BJ, Lee VW. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med 2014;27:1854–9.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, et al. Pre-eclampsia Part 2: prediction, prevention and management. Nat Rev Nephrol 2014;10:531–40.
   PubMed Web of Science ®Google Scholar
• Major HD, Campbell RA, Silver RM, et al. Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. Am J Obstet Gynecol 2014;210:547 e1–7.
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Bathgate S, et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonatal Med 2014;27:1038–48.
   PubMed Web of Science ®Google Scholar
• Lim R, Acharya R, Delpachitra P, et al. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol 2015;212:e1–86.12.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Sunderland N, Thornton C, et al. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy. Am J Obstet Gynecol 2017;216:170.e1–170.e8.
   Web of Science ®Google Scholar
• Biberoglu E, Kirbas A, Daglar K, et al. Serum angiogenic profile in abnormal placentation. J Matern Fetal Neonatal Med 2016;29:3193–7.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Whitten AE, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:1214–28.
   PubMed Web of Science ®Google Scholar
• Diguisto C, Piver E, Le Gouge A, et al. First trimester uterine artery Doppler, sFlt-1 and PlGF to predict preeclampsia in a high-risk population. J Matern Fetal Neonatal Med 2016. [Epub ahead of print]. doi: 10.1080/14767058.2016.1183631
   PubMed Web of Science ®Google Scholar
• Gallo DM, Wright D, Casanova C, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. Am J Obstet Gynecol 2016;214:619.e1–619.e17.
   Web of Science ®Google Scholar
• Kurtoglu E, Avci B, Kokcu A, et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med 2016;29:1987–92.
   PubMed Web of Science ®Google Scholar
• Lagana AS, Favilli A, Triolo O, et al. Early serum markers of pre-eclampsia: are we stepping forward? J Matern Fetal Neonatal Med 2016;29:3019–23.
   PubMed Web of Science ®Google Scholar
• O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol 2016;214:103e1–e12.
   Web of Science ®Google Scholar
• Yang J, Pearl M, DeLorenze GN, et al. Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors. Am J Obstet Gynecol 2016;215:359 e1–9.
   Web of Science ®Google Scholar
• Raijmakers MT, Peters WH, Steegers EA, Poston L. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta 2004;25(Suppl A):S85–9.
   PubMed Web of Science ®Google Scholar
• Roy S, Dhobale M, Dangat K, et al. Differential oxidative stress levels in mothers with preeclampsia delivering male and female babies. J Matern Fetal Neonatal Med 2015;28:1973–80.
   PubMed Web of Science ®Google Scholar
• Daglar K, Kirbas A, Timur H, et al. Placental levels of total oxidative and anti-oxidative status, ADAMTS-12 and decorin in early- and late-onset severe preeclampsia. J Matern Fetal Neonatal Med 2016;29:4059–64.
   PubMed Web of Science ®Google Scholar
• Liu X, Deng Q, Luo X, et al. Oxidative stress-induced Gadd45alpha inhibits trophoblast invasion and increases sFlt1/sEng secretions via p38 MAPK involving in the pathology of pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:3776–85.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Yang F, et al. Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia. Mol Biosyst 2011;7:2470–9.
   PubMed Web of Science ®Google Scholar
• Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 2012;68:258–70.
   PubMed Web of Science ®Google Scholar
• He Y, Xu B, Song D, et al. Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol 2016;76:205–11.
   PubMed Web of Science ®Google Scholar
• Kronborg CS, Gjedsted J, Vittinghus E, et al. Longitudinal measurement of cytokines in pre-eclamptic and normotensive pregnancies. Acta Obstet Gynecol Scand 2011;90:791–6.
   PubMed Web of Science ®Google Scholar
• Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol 2015;213:S115–S22.
   PubMed Web of Science ®Google Scholar
• Tuzcu ZB, Asicioglu E, Sunbul M, et al. Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women. Am J Obstet Gynecol 2015;213:533 e1–7.
   PubMed Web of Science ®Google Scholar
• Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996;106:127–33.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138–46.
   PubMedGoogle Scholar
• Saito S, Sakai M, Sasaki Y, et al. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999;117:550–5.
   PubMed Web of Science ®Google Scholar
• Saito S, Umekage H, Sakamoto Y, et al. Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am J Reprod Immunol 1999;41:297–306.
   PubMed Web of Science ®Google Scholar
• Borzychowski AM, Croy BA, Chan WL, et al. Changes in systemic type 1 and type 2 immunity in normal pregnancy and pre-eclampsia may be mediated by natural killer cells. Eur J Immunol 2005;35:3054–63.
   PubMed Web of Science ®Google Scholar
• Peixoto AB, Araujo Junior E, Ribeiro JU, et al. Evaluation of inflammatory mediators in the deciduas of pregnant women with pre-eclampsia/eclampsia. J Matern Fetal Neonatal 2016;29:75–9.
   PubMed Web of Science ®Google Scholar
• Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1-and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999;86:165–70.
   PubMed Web of Science ®Google Scholar
• Rein DT, Schondorf T, Gohring UJ, et al. Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia. J Reprod Immunol 2002;54:133–42.
   PubMed Web of Science ®Google Scholar
• Ozkan ZS, Simsek M, Ilhan F, et al. Plasma IL-17, IL-35, interferon-gamma, SOCS3 and TGF-beta levels in pregnant women with preeclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med 2014;27:1513–17.
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Peaceman AM, Wigton TR, et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752–7. discussion 7–9.
   PubMed Web of Science ®Google Scholar
• Meekins JW, McLaughlin PJ, West DC, et al. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994;98:110–14.
   PubMed Web of Science ®Google Scholar
• Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20–5.
   PubMedGoogle Scholar
• Lau SY, Guild SJ, Barrett CJ, et al. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am J Reprod Immunol 2013;70:412–27.
   PubMed Web of Science ®Google Scholar
• Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989;258:301–4.
   PubMed Web of Science ®Google Scholar
• Peine M, Marek RM, Lohning M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 2016;37:321–33.
   PubMed Web of Science ®Google Scholar
• Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011;7:321–9.
   PubMed Web of Science ®Google Scholar
• Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166–74.
   PubMed Web of Science ®Google Scholar
• Aoki S, Hayakawa M, Ozaki H, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010;335:75–81.
   PubMed Web of Science ®Google Scholar
• Topping V, Romero R, Than NG, et al. Interleukin-33 in the human placenta. J Matern Fetal Neonatal Med 2013;26:327–38.
   PubMed Web of Science ®Google Scholar
• Granne I, Southcombe JH, Snider JV, et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS One 2011;6:e24463.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Chaiworapongsa T, Romero R, et al. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med 2013;26:1359–70.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Chaiworapongsa T, Romero R, et al. Soluble ST2, a modulator of the inflammatory response, in preterm and term labor. J Matern Fetal Neonatal Med 2014;27:111–21.
   PubMed Web of Science ®Google Scholar
• Kaitu'u-Lino TJ, Tuohey L, Tong S. Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. J Reprod Immunol 2012;95:46–9.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Romero R, Korzeniewski SJ, et al. Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the anti-inflammatory limb of the immune response. J Matern Fetal Neonatal Med 2013;26:1384–93.
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159–67.
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143–8.
   PubMed Web of Science ®Google Scholar
• Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163–8.
   PubMed Web of Science ®Google Scholar
• Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–74.
   PubMed Web of Science ®Google Scholar
• Douglas B, Maechler M, Bolker B. lme4: Linear mixed-effects models using S4 classes.R package version 0.999999-0. Available from: http://CRAN.R-project.org/package=lme4 2012.
   Google Scholar
• Haslett C, Savill JS, Meagher L. The neutrophil. Curr Opin Immunol 1989;2:10–18.
   PubMed Web of Science ®Google Scholar
• Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 1989;86:5708–12.
   PubMed Web of Science ®Google Scholar
• Bollapragada S, Youssef R, Jordan F, et al. Term labor is associated with a core inflammatory response in human fetal membranes, myometrium, and cervix. Am J Obstet Gynecol 2009;200:104 e1–11.
   Web of Science ®Google Scholar
• Mendelson CR. Minireview: fetal–maternal hormonal signaling in pregnancy and labor. Mol Endocrinol 2009;23:947–54.
   PubMed Web of Science ®Google Scholar
• Southcombe JH, Redman CW, Sargent IL, Granne I. Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia. Clin Exp Immunol 2015;181:480–90.
   PubMed Web of Science ®Google Scholar
• Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001;185:1118–23.
   PubMed Web of Science ®Google Scholar
• Fock V, Mairhofer M, Otti GR, et al. Macrophage-derived IL-33 is a critical factor for placental growth. J Immunol 2013;191:3734–43.
   PubMed Web of Science ®Google Scholar
• Pakandl M, Pecka Z. A domestic duck as a new host for Blastocystis sp. Folia Parasitol 1992;39:59–60.
   PubMed Web of Science ®Google Scholar
• Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930–5.
   PubMed Web of Science ®Google Scholar
• Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem/FEBS 1999;264:397–406.
   PubMedGoogle Scholar
• Tominaga S, Kuroiwa K, Tago K, et al. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 1999;264:14–18.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–90.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051–4.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779–86.
   PubMed Web of Science ®Google Scholar
• Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046–55.
   PubMed Web of Science ®Google Scholar
• Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526–34.
   PubMed Web of Science ®Google Scholar
• Gajardo Carrasco T, Morales RA, Perez F, et al. Alarmin' immunologists: IL-33 as a putative target for modulating T cell-dependent responses. Front Immunol 2015;6:232.
   PubMed Web of Science ®Google Scholar
• Eda Gokdemir I, Ozdegirmenci O, Elmas B, et al. Evaluation of ADAMTS12, ADAMTS16, ADAMTS18 and IL-33 serum levels in pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:2451–6.
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem 1997;121:95–103.
   PubMed Web of Science ®Google Scholar
• Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166:6633–9.
   PubMed Web of Science ®Google Scholar
• Takezako N, Hayakawa M, Hayakawa H, et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006;341:425–32.
   PubMed Web of Science ®Google Scholar
• Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373–9.
   PubMed Web of Science ®Google Scholar
• Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994;13:1176–88.
   PubMed Web of Science ®Google Scholar
• McGill SN, Ahmed NA, Hu F, et al. Shedding of L-selectin as a mechanism for reduced polymorphonuclear neutrophil exudation in patients with the systemic inflammatory response syndrome. Arch Surg 1996;131:1141–6. discussion 7.
   PubMed Web of Science ®Google Scholar
• Mildner M, Storka A, Lichtenauer M, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010;87:769–77.
   PubMed Web of Science ®Google Scholar
• Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997;235:474–8.
   PubMed Web of Science ®Google Scholar
• Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013;60:16–26.
   PubMed Web of Science ®Google Scholar
• Zeyda M, Wernly B, Demyanets S, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 2013;37:658–65.
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002;299:18–24.
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002;32:1520–6.
   PubMed Web of Science ®Google Scholar
• Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468–73.
   PubMed Web of Science ®Google Scholar
• Becerra A, Warke RV, de Bosch N, et al. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008;41:114–20.
   PubMed Web of Science ®Google Scholar
• Houghton-Trivino N, Salgado DM, Rodriguez JA, et al. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol 2010;91:697–706.
   PubMed Web of Science ®Google Scholar
• Guerrero CD, Arrieta AF, Ramirez ND, et al. High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue. Cytokine 2013;61:766–71.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961–6.
   PubMed Web of Science ®Google Scholar
• Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186–90.
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538–49.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936–44.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721–6.
   PubMed Web of Science ®Google Scholar
• Shah RV, Januzzi JL Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010;7:9–14.
   PubMedGoogle Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339–46.
   PubMed Web of Science ®Google Scholar
• Hoogerwerf JJ, Tanck MW, van Zoelen MA, et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010;36:630–7.
   PubMed Web of Science ®Google Scholar
• Lecart S, Lecointe N, Subramaniam A, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002;32:2979–87.
   PubMed Web of Science ®Google Scholar
• Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010;107:8017–22.
   PubMed Web of Science ®Google Scholar
• Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010;49:520–7.
   PubMed Web of Science ®Google Scholar
• Sahlander K, Larsson K, Palmberg L. Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities. J Occup Environ Med/Am Coll Occup Environ Med 2010;52:214–18.
   PubMed Web of Science ®Google Scholar
• Shynlova O, Lee YH, Srikhajon K, Lye SJ. Physiologic uterine inflammation and labor onset: integration of endocrine and mechanical signals. Reprod Sci 2013;20:154–67.
   PubMed Web of Science ®Google Scholar
• Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003;124:1206–14.
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Kuroiwa K, Tokunaga T, et al. Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid. Respir Med 2001;95:532–3.
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277–81.
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369–80.
   PubMed Web of Science ®Google Scholar
• Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772–81.
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 2011;155:12–20.
   PubMed Web of Science ®Google Scholar
• Curry AE, Vogel I, Skogstrand K, et al. Maternal plasma cytokines in early-and mid-gestation of normal human pregnancy and their association with maternal factors. J Reprod Immunol 2008;77:152–60.
   PubMed Web of Science ®Google Scholar
• Harper M, Li L, Zhao Y, et al. Change in mononuclear leukocyte responsiveness in midpregnancy and subsequent preterm birth. Obstet Gynecol 2013;121:805–11.
   PubMed Web of Science ®Google Scholar
• Christian LM, Porter K. Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: effects of maternal body mass index. Cytokine 2014;70:134–40.
   PubMed Web of Science ®Google Scholar
• Young BC, Stanic AK, Panda B, et al. Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum. Am J Obstet Gynecol 2014;210: 445 e1–6.
   Web of Science ®Google Scholar
• Romero R, Parvizi ST, Oyarzun E, et al. Amniotic fluid interleukin-1 in spontaneous labor at term. J Reprod Med 1990;35:235–8.
   PubMed Web of Science ®Google Scholar
• Keelan JA, Marvin KW, Sato TA, et al. Cytokine abundance in placental tissues: evidence of inflammatory activation in gestational membranes with term and preterm parturition. Am J Obstet Gynecol 1999;181:1530–6.
   PubMed Web of Science ®Google Scholar
• Maymon E, Ghezzi F, Edwin SS, et al. The tumor necrosis factor alpha and its soluble receptor profile in term and preterm parturition. Am J Obstet Gynecol 1999;181:1142–8.
   PubMed Web of Science ®Google Scholar
• Haddad R, Tromp G, Kuivaniemi H, et al. Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol 2006;195:394 e1–24.
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Haddad R, et al. The transcriptome of the uterine cervix before and after spontaneous term parturition. Am J Obstet Gynecol 2006;195:778–86.
   PubMed Web of Science ®Google Scholar
• Norman JE, Bollapragada S, Yuan M, Nelson SM. Inflammatory pathways in the mechanism of parturition. BMC Pregnancy Childbirth 2007;7:S7.
   PubMedGoogle Scholar
• Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev 2007;65:S194–S202.
   PubMed Web of Science ®Google Scholar
• Romero R, Xu Y, Plazyo O, et al. A role for the inflammasome in spontaneous labor at term. Am J Reprod Immunol 2016. [Epub ahead of print]. doi: 10.1111/aji.12440
   Web of Science ®Google Scholar
• Ogge G, Romero R, Chaiworapongsa T, et al. Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. J Matern Fetal Neonatal Med 2010;23:476–87.
   PubMed Web of Science ®Google Scholar
• Ogge G, Chaiworapongsa T, Romero R, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011;39:641–52.
   PubMed Web of Science ®Google Scholar
• Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80–6.
   PubMed Web of Science ®Google Scholar
• Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013;94:247–57.
   PubMed Web of Science ®Google Scholar
• Harmon AC, Cornelius DC, Amaral LM, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) 2016;130:409–19.
   PubMed Web of Science ®Google Scholar
• Sabatier F, Bretelle F, D'Ercole C, et al. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol 2000;183:1558–63.
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792–7.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Gervasi MT, Refuerzo J, et al. Maternal lymphocyte subpopulations (CD45RA + and CD45RO+) in preeclampsia. Am J Obstet Gynecol 2002;187:889–93.
   PubMed Web of Science ®Google Scholar
• Peraçoli JC, Bannwart-Castro CF, Romao M, et al. High levels of heat shock protein 70 are associated with pro-inflammatory cytokines and may differentiate early- from late-onset preeclampsia. J Reprod Immunol 2013;100:129–34.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao Y, Zhang L, et al. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. Hypertens Pregnancy 2013;32:270–80.
   PubMed Web of Science ®Google Scholar
• Southcombe JH, Benton SJ, Hu Y, et al. Measurement of sST2 is comparable to PlGF in the diagnosis of early-onset pre-eclampsia. Pregnancy Hypertens 2013;3:115–17.
   PubMed Web of Science ®Google Scholar
• Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006;11:309–16.
   PubMed Web of Science ®Google Scholar
• Luppi P, Tse H, Lain KY, et al. Preeclampsia activates circulating immune cells with engagement of the NF-kappaB pathway. Am J Reprod Immunol 2006;56:135–44.
   PubMed Web of Science ®Google Scholar
• Mihu D, Sabau L, Costin N, et al. Implications of maternal systemic oxidative stress in normal pregnancy and in pregnancy complicated by preeclampsia. J Matern Fetal Neonatal Med 2012;25:944–51.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004;44:708–14.
   PubMed Web of Science ®Google Scholar
• Jonsson Y, Ruber M, Matthiesen L, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006;70:83–91.
   PubMed Web of Science ®Google Scholar
• Vitoratos N, Economou E, Iavazzo C, et al. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. Mediators Inflamm 2010;2010:908649.
   PubMed Web of Science ®Google Scholar
• Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007;58:21–30.
   PubMed Web of Science ®Google Scholar
• Xiao JP, Yin YX, Gao YF, et al. The increased maternal serum levels of IL-6 are associated with the severity and onset of preeclampsia. Cytokine 2012;60:856–60.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83.
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137–42.
   PubMed Web of Science ®Google Scholar
• Baumann MU, Bersinger NA, Mohaupt MG, et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008;199:266.e1–6.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–87.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SY, Park SY, et al. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenatal Diagn 2009;29:471–6.
   PubMed Web of Science ®Google Scholar
• Foidart JM, Munaut C, Chantraine F, et al. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol 2010;35:680–7.
   PubMed Web of Science ®Google Scholar
• Korzeniewski SJ, Romero R, Chaiworapongsa T, et al. Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. Am J Obstet Gynecol 2016;214:629.e1–e17.
   PubMed Web of Science ®Google Scholar